Key clinical point: Romosozumab, with its dual function, has a positive role in the treatment of patients with osteoporosis and low bone mineral density (BMD).

Major finding: Different doses of romosozumab (210, 140, and 70 mg) resulted in a significant increase in BMD at the lumbar spine, total hip, and femoral neck compared with alendronate, teriparatide, and placebo. Romosozumab 210 mg was more effective than doses of 140 and 70 mg in increasing BMD. Adjudicated cardiovascular serious adverse events and cardiovascular deaths were more with romosozumab 210 mg vs. the placebo.

Study details: Meta-analysis of 7 studies including 6,393 patients initially treated with different doses of romosozumab.

Disclosures: This research was supported by a grant from the Iran University of Medical Sciences. The authors declared no conflicts of interest.